All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @itsjohannanavarro on TikTok · 106s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @itsjohannanavarro's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm starting week seven on Mungaro
  2. 0:02and I am upping my dose today to the five milligrams.
  3. 0:05I'm not gonna lie, I am kinda nervous,
  4. 0:07but if I do get any symptoms,
  5. 0:08I definitely will document it tonight.
  6. 0:10If I get any, cause I usually do feel symptoms right away.
  7. 0:13Like I'm talking within like two to four hours
  8. 0:15of the medication, I feel things, okay?
  9. 0:18I start feeling stuff.
  10. 0:19If you like tomorrow, I definitely will feel something.
  11. 0:21So I will document that for you guys.
  12. 0:24So I've gotten a few DM saying
  13. 0:25that you guys have gone to Mexico to get these pens.
  14. 0:29Okay, it has no needle on it.
  15. 0:31The two pharmacies that I've gone to,
  16. 0:32they automatically just give me the needles.
  17. 0:34This is what they look like.
  18. 0:35I literally didn't have to say anything.
  19. 0:37They literally just like tard up the Mungaro
  20. 0:39and like as we're talking and stuff,
  21. 0:40they automatically get them, then scan them through
  22. 0:43and they are also free.
  23. 0:44Like it scans like the price
  24. 0:45and then they deduct the price of the needles.
  25. 0:48This is what they look like.
  26. 0:49They have a few in here.
  27. 0:51If you give you the full box,
  28. 0:52when you just need four, pick the four doses in one pen.
  29. 0:55I've also gotten questions.
  30. 0:56If I leave the same needle or change it,
  31. 0:58anytime you do a new dose,
  32. 1:00you have to replace the needle,
  33. 1:02throw it away when you're done.
  34. 1:03This Mungaro, I'm getting nervous.
  35. 1:05I'm gonna rub it with alcohol, open it.
  36. 1:08You're gonna poke it on there and twist.
  37. 1:11You're gonna remove this and you're gonna remove this.
  38. 1:13We just twist it until it stops, until it has a one.
  39. 1:17But it literally just, it won't go anymore
  40. 1:19and it shows a little one.
  41. 1:21And that just means one dose of five milligrams.
  42. 1:24I had my boiled eggs.
  43. 1:25I'm about to have a protein shake
  44. 1:28and I'm gonna make sure I drink a lot of water tonight.
  45. 1:30Just, ah.
  46. 1:32You're good.
  47. 1:37This is my biggest insecurity off right here.
  48. 1:39The fat right here under my bra.
  49. 1:42So yeah, here is two week number seven.

Week 7 GLP-1 progress posts: what they don't tell you

ItsJohanna💕

TikTok creator

49.4K viewsWatch on TikTok

Quick answer

The creator is self-administering tirzepatide 5 mg subcutaneously and documents her dose escalation process, injection technique, and anticipated gastrointestinal side effects on TikTok. She also references sourcing the medication from pharmacies in Mexico, which raises regulatory and supply-chain safety considerations that are not addressed in the video. Her needle-per-dose advice aligns with manufacturer and clinical guidance, but the specific side effect onset window she describes is anecdotal and not consistent with tirzepatide's published pharmacokinetic data.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Week 7 GLP-1 progress posts: what they don't tell you, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Week 7 GLP-1 progress posts: what they don't tell you is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Week 7 GLP-1 progress posts: what they don't tell you" from ItsJohanna💕. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-administering tirzepatide 5 mg subcutaneously and documents her dose escalation process, injection technique, and anticipated gastrointestinal side effects on TikTok.

The reason this review is not generic is the source wording and the canonical claim label "glp1 starting week 7." In this clip, the useful excerpt is: "I'm starting week seven on Mungaro and I am upping my dose today to the five milligrams." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide peak plasma concentration occurs 8 to 72 hours post-dose per Eli Lilly prescribing information (2022), not consistently within two to four hours as described.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is self-administering tirzepatide 5 mg subcutaneously and documents her dose escalation process, injection technique, and anticipated gastrointestinal side effects on TikTok.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is self-administering tirzepatide 5 mg subcutaneously and documents her dose escalation process, injection technique, and anticipated gastrointestinal side effects on TikTok. She also references sourcing the medication from pharmacies in Mexico, which raises regulatory and supply-chain safety considerations that are not addressed in the video. Her needle-per-dose advice aligns with manufacturer and clinical guidance, but the specific side effect onset window she describes is anecdotal and not consistent with tirzepatide's published pharmacokinetic data.
  • Single-use pen needles per dose is the correct standard: Kreider and Gabriele (2019, Diabetes Technology and Therapeutics) found reuse causes tip deformation and elevated infection risk.
  • Tirzepatide peak plasma concentration occurs 8 to 72 hours post-dose per Eli Lilly prescribing information (2022), not consistently within two to four hours as described.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Single-use pen needles per dose is the correct standard: Kreider and Gabriele (2019, Diabetes Technology and Therapeutics) found reuse causes tip deformation and elevated infection risk.
  • Tirzepatide peak plasma concentration occurs 8 to 72 hours post-dose per Eli Lilly prescribing information (2022), not consistently within two to four hours as described.
  • In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), nausea occurred in about 31% of patients on the 5 mg dose, but individual timing and severity varied substantially.
  • FDA regulations do not permit personal importation of tirzepatide from foreign pharmacies, and cold-chain integrity for temperature-sensitive biologics cannot be verified in informal cross-border purchases.
  • Alcohol site prep before subcutaneous injection is recommended by both the CDC and ADA as a basic infection-prevention step, and Johanna gets this right.
  • Dose escalation decisions for tirzepatide should be guided by a licensed prescriber, not timed based on another person's symptom experience as described on social media.
  • Manufacturer patient assistance programs and licensed telehealth platforms exist for cost and access barriers and carry legal and safety protections that informal foreign sourcing does not.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @itsjohannanavarro actually say?

Johanna is in week seven of tirzepatide (she says "Mungaro," which is Mounjaro) and is stepping up to the 5 mg dose. She walks through her injection prep on camera, including swabbing with alcohol, attaching a needle, and dialing to one dose. She also addresses DMs about sourcing Mounjaro in Mexico and states needles were automatically provided and scanned as free at the pharmacy. Her core needle advice: "anytime you do a new dose, you have to replace the needle, throw it away when you're done."

She mentions feeling effects within two to four hours of the dose and describes eating boiled eggs and planning a protein shake beforehand. This is a practical, self-filmed injection tutorial with personal commentary, not a medical prescription or formal guidance.

Does the science back this up?

Her needle-change advice is correct and clinically supported. The rest lands in a gray zone, especially the timeline for feeling effects and the implication that side effects arriving fast is normal and expected.

On needle reuse: a 2019 review by Kreider and Gabriele in Diabetes Technology and Therapeutics confirmed that reusing insulin pen needles increases injection site trauma, raises infection risk, and can damage the needle tip enough to alter drug delivery. Tirzepatide uses the same pen-needle system, so the same logic applies. Johanna is right to tell her audience to swap needles every dose.

On onset of side effects: tirzepatide's pharmacokinetic profile shows a time to peak plasma concentration of roughly 8 to 72 hours after subcutaneous injection (Eli Lilly prescribing information, 2022). Gastrointestinal effects in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) were most common in the hours to days following injection, but there is no clinical basis for a consistent "two to four hour" symptom window as a reliable rule.

What did they get wrong (or right)?

Credit where it is due: the needle hygiene advice is accurate and genuinely useful. A lot of GLP-1 content online glosses over this entirely.

What is less solid: the "two to four hours" symptom claim is presented as near-certain personal fact that could shape how viewers interpret their own experience. Someone who does not feel anything at two hours might assume the dose did not work. That is a real downstream risk of framing anecdotal timing as a reliable benchmark.

The Mexico sourcing discussion deserves scrutiny. Johanna does not explicitly recommend buying medication abroad, but she responds to DMs about it in a way that normalizes the practice. Mounjaro purchased at a foreign pharmacy may not be stored, handled, or verified under the same regulatory standards as U.S.-dispensed product. The FDA has not approved importation of tirzepatide for personal use, and cold-chain integrity is a legitimate concern. This is not a trivial detail for a 49,000-view video.

The injection technique she demonstrates, attaching the needle, priming to show flow, and injecting, appears broadly consistent with Eli Lilly's published patient instructions, though a trained pharmacist or clinician should always be the primary source for technique guidance.

What should you actually know?

If you are on tirzepatide or considering it, the needle point is worth taking seriously. Single-use pen needles are not a suggestion. Reusing them causes microscopic barbing that increases pain and can introduce bacteria at the injection site.

The side effect timing question is more nuanced than most content creators acknowledge. In the SURMOUNT-1 trial, nausea affected roughly 31% of patients at the 5 mg dose, but individual timing varied considerably. Your body is not running on the same schedule as someone else's TikTok. Expecting symptoms at a specific hour window based on one person's experience can cause unnecessary anxiety or false reassurance.

Sourcing GLP-1 medications outside the U.S. through unverified channels carries real risks: counterfeit product, cold-chain failures, and no legal recourse if something goes wrong. If cost or access is the barrier, licensed telehealth platforms and manufacturer savings programs are a safer starting point than foreign pharmacy tourism.

Finally, nothing in this video constitutes medical advice, and nothing in this fact-check does either. Dose decisions, injection site selection, and side effect management should involve a licensed prescriber who knows your full health history.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

ItsJohanna💕 · TikTok creator

49.4K views on this video

Starting Week 7! 😊

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about single-use pen needles per dose?

Single-use pen needles per dose is the correct standard: Kreider and Gabriele (2019, Diabetes Technology and Therapeutics) found reuse causes tip deformation and elevated infection risk.

What does the video say about tirzepatide peak plasma concentration occurs 8 to 72 hours post-dose?

Tirzepatide peak plasma concentration occurs 8 to 72 hours post-dose per Eli Lilly prescribing information (2022), not consistently within two to four hours as described.

What does the video say about in the surmount-1 trial (jastreboff et al., 2022, nejm), nausea?

In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), nausea occurred in about 31% of patients on the 5 mg dose, but individual timing and severity varied substantially.

What does the video say about fda regulations do not permit personal importation of tirzepatide from?

FDA regulations do not permit personal importation of tirzepatide from foreign pharmacies, and cold-chain integrity for temperature-sensitive biologics cannot be verified in informal cross-border purchases.

What does the video say about alcohol site prep before subcutaneous injection?

Alcohol site prep before subcutaneous injection is recommended by both the CDC and ADA as a basic infection-prevention step, and Johanna gets this right.

Dose escalation decisions for tirzepatide should be guided by a licensed prescriber, not timed based on another person's symptom experience as described on social media?

Dose escalation decisions for tirzepatide should be guided by a licensed prescriber, not timed based on another person's symptom experience as described on social media.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ItsJohanna💕, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.